13F Data
13F filer · CIK 1844645

Pivotal bioVenture Partners Investment Advisor LLC

SAN FRANCISCO, CA · filing since Q4 2020 · last filing Aug 13, 2026
Reported value
$307.8M
+$28.0M vs prior
Positions
13
New / sold out
1 / 1
Added / reduced
3 / 4
Turnover
2.6%
buys $41.0M · sells $7.5M
Top-10 weight
95.1%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewAVALYN PHARMACEUTICALS INC+966,792–+$31.8M
AddedTREVI THERAPEUTICS INC+188,946+12.2%+$3.5M
AddedVAXCYTE INC+53,045+3.9%+$3.1M
AddedAVALO THERAPEUTICS INC+138,100+46.7%+$2.6M

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedZENAS BIOPHARMA INC-101,225-17.1%$-2.6M
ReducedOCULIS HOLDING AG-174,033-10.4%$-2.4M
ReducedARCUTIS BIOTHERAPEUTICS INC-90,609-6.7%$-2.4M
Sold outBOLT BIOTHERAPEUTICS INC-42,581-100.0%$-172.0K
ReducedMAPLIGHT THERAPEUTICS INC-1-0.0%$-36

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2020: $303.3MQ1 2021: $311.7MQ2 2021: $253.7MQ3 2021: $282.9MQ4 2021: $239.2MQ1 2022: $211.3MQ2 2022: $198.5MQ3 2022: $273.7MQ4 2022: $230.0MQ1 2023: $242.9MQ2 2023: $303.3MQ3 2023: $250.7MQ4 2023: $394.2MQ1 2024: $155.6MQ2 2024: $130.1MQ3 2024: $168.5MQ4 2024: $148.1MQ1 2025: $123.6MQ2 2025: $161.3MQ3 2025: $173.0MQ4 2025: $258.7MQ1 2026: $279.8MQ2 2026: $307.8M
Q4 2020Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1VAXCYTE INCCOM1,425,470$82.9M26.92%
2ARCUTIS BIOTHERAPEUTICS INCCOM1,265,283$33.2M10.78%
3TREVI THERAPEUTICS INCCOM1,742,672$32.5M10.56%
4AVALYN PHARMACEUTICALS INCCOM SHS966,792$31.8M10.34%
5EVOMMUNE INCCOM SHS1,926,943$25.6M8.32%
6MAPLIGHT THERAPEUTICS INCCOM611,446$21.9M7.12%
7OCULIS HOLDING AGORDINARY SHARES1,506,250$20.9M6.79%
8BIOAGE LABS INCCOM653,374$16.0M5.20%
9IMMUNOME INCCOM732,512$15.5M5.04%
10ZENAS BIOPHARMA INCCOM490,766$12.5M4.05%
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.